Patricia J. Hollen, PhD, RN
Oncology nursing interventions in Quality of Life outcomes
Dr. Patricia Hollen is the Boyd Professor of Oncology Nursing at the University of Virginia. She is chair of the Cancer Center Nursing Research Council (CCNRC), working with 10 members from the School of Nursing and Cancer Center who are interested in cancer research. She is co-chair of several interdisciplinary research study groups (lung cancer, breast cancer, and brain tumors) that have been formed by the CCNRC.
Her research interest lies in understanding the effect of intervention on quality of life for different high-risk populations. For cancer-surviving adolescents, her intervention has been focused on refining decision-making skills to reduce risk behaviors, which is an area of increasing national emphasis due to late effects of treatment. She recently completed a large outcomes grant from the Oncology Nursing Society Foundation and now has an application, A Decision Aid for Cancer-Surviving Adolescents, in review at NIH.
For adults with the progressive disease of lung cancer, her emphasis has been on measurement of quality of life as an endpoint for testing new therapies during clinical trials. She has been one of the developers of the Lung Cancer Symptom Scale (LCSS), which has been used for over 15 years on six continents by many of the major pharmaceutical companies. She has been a consultant for these clinical trials related to symptomatology and quality of life as an endpoint. The original LCSS was evaluated for feasibility, reliability, and validity in nearly 1,000 lung cancer patients at eight cancer centers in the U.S. and Canada. The outcomes have been published in journals such as Cancer, European Journal of Cancer, Lung Cancer, and Supportive Care in Cancer. The measure now has 46 tested languages. An electronic (hand-held pc) version is being tested in a 10-site community practice study in Canada. Hollen has also been a part of two studies that have determined an appropriate interval for quality of life assessment in clinical trials for lung malignancies. She has been the primary investigator examining models related to symptoms during treatment and their effect on quality of life for two populations: 144 patients with lung cancer from six cancer centers in the U.S.; 495 patients with mesothelioma from 19 countries. She is an invited speaker to the 11th World Conference on Lung Cancer in Barcelona, Spain in 2005 and she is currently waiting to hear the outcome of an NIH application, A Decision Aid for Patients with Advanced Lung Cancer, which has a fundable score from NIH.